OncLive TV

Naveen Pemmaraju, MD, discusses phase 2 data with pivekimab sunirine in frontline or relapsed/refractory blastic plasmacytoid dendritic cell neoplasms.

Lydia Scarfò, MD, discusses early safety findings with the BTK degrader BGB-16673 in R/R CLL/SLL

Johannes Schetelig, MD, discusses challenges with assessing haploidentical related vs mismatched unrelated donor transplantation in high-risk AML/ALL/MDS

Andrea Visentin, MD, discusses data from an Italian cost analysis of treatment sequencing in CLL.

Balazs Halmos, MD, discusses treatment sequencing considerations in the second line and beyond in NSCLC.

Zeynep Eroglu, MD, discusses management strategies for safe and effective use of encorafenib, binimetinib,and nivolumab in BRAF V600–mutant melanoma.

Neeta Somaiah, MD, discusses the landscape of mutation-specific therapy for the treatment of patients with a gastrointestinal stromal tumor.

Dana E. Rathkopf, MD, discusses the clinical significance of findings from the phase 3 AMPLITUDE trial in HRR gene–mutated mCSPC.

Mats Jerkeman, MD, discusses the use of induction chemoimmunotherapy followed by high-dose chemotherapy and ASCT in younger patients with MCL.

Gerhardt Attard, MD, PhD, FRCP, discusses niraparib plus abiraterone acetate and prednisone in mCSPC with HRR gene alterations.

Jens Bedke, MD, discusses the safety of enfortumab vedotin and pembrolizumab in previously untreated locally advanced or metastatic urothelial carcinoma.

Ajay K. Gopal, MD, FACP, discusses the significance of the FDA approval of tafasitamab for patients with relapsed/refractory follicular lymphoma.

Katherine C. Ansley, MD, highlights the role of elacestrant in treating ER-positive, HER2-negative, ESR1-mutant, advanced breast cancer with metastases.

Zeynep Eroglu, MD, discusses the rationale for evaluating encorafenib plus binimetinib and nivolumab in BRAF V600-mutant melanoma with brain metastases.

R. Lor Randall, MD, FACS, discusses how suboptimal access to multidisciplinary, coordinated care remains a critical barrier to optimal outcomes in sarcoma.

Jessica Paulus, ScD, discusses the clinical implications of using real-world data to add an external control arm to a phase 2 study in HER2+ breast cancer.

Sumanta Kumar Pal, MD, FASCO, discusses future directions using genomic data from the phase 3 IMmotion010 trial.

Jonathan Wesley Riess, MD, MS, outlines treatment sequencing considerations for KRAS- and BRAF-targeted therapies in NSCLC.

Sumanta Kumar Pal, MD, FASCO, discusses data supporting KIM-1 as a potential biomarker to inform adjuvant immunotherapy use in high-risk resected RCC.

Linda R. Duska, MD, MPH, discusses the background of the phase 3 KEYNOTE-A18 trial of pembrolizumab plus chemoradiotherapy in cervical cancer.

Alicia Morgans, MD, MPH, discusses enzalutamide plus radium-223 in with metastatic castration-resistant prostate cancer.

Timothy R. Gershon, MD, PhD, discusses ongoing research priorities neurofibromatosis type 1–associated plexiform neurofibromas

Paolo Ghia, MD, highlights the rationale for evaluating pirtobrutinib for the treatment of patients with relapsed/refractory CLL.

Eileen M. O’Reilly, MD, discusses the potential of tumor treating fields for the treatment of patients with locally advanced pancreatic cancer.

Jens Bedke, MD, discusses findings from subgroup analyses of the phase 3 EV-302/KEYNOTE-A39 trial in untreated metastatic urothelial cancer.

Narjust Florez, MD, discusses emerging strategies to address immune checkpoint inhibitor resistance in non–small cell lung cancer.

Narjust Florez, MD, discusses current treatment preferences in frontline IO for BRAF V600E–mutated metastatic non–small cell lung cancer.

Marina Kremyanskaya, MD, PhD, discusses safety and early efficacy findings with divesiran in polycythemia vera.

Martin Dietrich, MD, PhD, discusses the FDA accelerated approval of zongertinib for HER2-mutated or metastatic nonsquamous NSCLC.

Rachel E. Sanborn, MD, discusses preclinical and early clinical data supporting the use of the IB6-directed ADC sigvotatug vedotin in patients with NSCLC.